Status:

COMPLETED

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Lead Sponsor:

University of California, San Diego

Conditions:

Keloid

Eligibility:

All Genders

18-80 years

Phase:

EARLY_PHASE1

Brief Summary

Keloids are a common form of hypertrophic scars that by definition last beyond 6 months and grow beyond the site of initial injury. Keloids are a common complaint from patients in dermatology and caus...

Eligibility Criteria

Inclusion

  • Adults aged 18 to 80
  • History of keloid scar for at least 12 months
  • Absence of keloid treatment for past 12 months
  • Participant must have a keloid scar of at least 4cm in length.
  • Participants who score at least 8 or higher on the Vancouver Scar Scale
  • Subjects who score 5 (neither satisfied nor dissatisfied) to 10 (maximally dissatisfied) on the patient subjective score of dissatisfaction with keloid.
  • Participants must be in stable health, as confirmed by medical history, per investigator judgment
  • Participants must be able to read, sign, and understand the informed consent
  • Participants must be willing to avoid any other treatments to the keloid that will be treated including corticosteroid injections, surgical excision, chemotherapeutic injection, lasers, light-based therapy, radiation therapy, cryotherapy, or pressure therapy, during the study period.

Exclusion

  • Pregnant women
  • Keloids on face, neck or scalp
  • History of hypersensitivity to botulinum toxin
  • Ongoing or planned treatment with chemotherapy, radiation, isotretinoin, cytokine-based immunotherapies
  • Any planned surgery during study period
  • Known diagnosis of insulin dependent diabetes mellitus
  • Patients being treating with dupilumab for any indication
  • Patients taking aminoglycoside antibiotics
  • Patients with pre-existing neuromuscular disorders
  • Patients with infection around potential injection sites

Key Trial Info

Start Date :

March 11 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 31 2023

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT05330078

Start Date

March 11 2022

End Date

May 31 2023

Last Update

November 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California San Diego

San Diego, California, United States, 92122